Abstract
Ensuring safe drinking water is one of the top priorities in public health as waterborne diseases remain a global challenge. In China, microbial contamination in drinking water is a particular concern and comprehensive survey/monitoring of the drinking water microbiome is necessary. However, traditional culture-based microbial monitoring methods have significant limitations, and nationwide tap water survey/monitoring in China would require significant resources. Here, a cost-effective citizen science approach was developed to collect household drinking water samples (n = 50) from 19 provinces in China during December 2020 to August 2021. Using a protocol optimized for low-biomass samples, 22 out of 50 tap water samples were tested positive for microbial DNA. The PCR products were pooled for 16S rRNA genes metabarcoding to elucidate the tap water microbiome and detect waterborne pathogens, yielding 7,635 Amplicon Sequence Variants (ASVs). Outdoor temperature was found to be the first-order driver of total microbial community structure, validating our citizen science approach against previous studies. Alarmingly, pathogenic bacteria including Mycobacterium spp., Acinetobacter spp., and Legionella spp. were detected in all PCR positive samples. More importantly, elevated proportions or new appearance of toxin-producing cyanobacteria (e.g., Microcystis spp.) and pathogenic species (e.g., Salmonella enterica) were evident in local tap water samples after the extreme rainstorm event in Zhengzhou on July 20, 2021, and Typhoon In-Fa Landfall. High pathogen relative abundances were found to be significantly correlated with high outdoor temperatures. This underscores the need for enhanced drinking water treatment protocols during and following extreme rainfall events and/or periods of high temperatures, particularly relevant in the face of global climate change.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Duke Kunshan University (DKU).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are contained in the manuscript, the supplementary materials, and Zenodo (unpublished), while codes for data analysis are available upon reasonable request to the authors.
Non-standard abbreviations
- RA
- Relative abundance
- CS
- Citizen science sampling protocol and materials
- SM
- Supplementary material
- NC
- Nanchang, Jiangxi
- XA
- Xi’an, Shanxi
- NJ
- Nanjing, Jiangsu
- HZ
- Huizhou, Guangdong
- JN
- Jinan, Shandong
- ZZ
- Zhengzhou, Henan
- CZ
- Changzhou, Jiangsu
- SH
- Shanghai
- ZB
- Zibo, Shandong
- MA
- Macau
- BJ
- Beijing
- TJ
- Tianjin
- CQ
- Chongqing
- LJ
- Lijiang, Yunnan
- LZ
- Lanzhou, Gansu
